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INTRODUCTION
BRCA1 is a large nuclear phospho-protein that regulates the repair of double-strand breaks (DSBs) in DNA. It contains an N-terminal RING domain that functions as an E3 ubiquitin ligase when bound to its partner protein BARD1 (1) . BRCA1 also contains a Cterminal BRCT repeat domain (2) , that functions as phospho-protein binding module (3, 4) . BACH1, a helicase involved in DNA repair, is one important interacting partner that binds to the BRCT repeats of BRCA1 (5) . Mutations affecting both domains are associated with hereditary cancer (6) , suggesting that the function of both domains is necessary for the ability of BRCA1 to suppress tumor formation. However, the functional contribution of each structural domain to the overall ability of BRCA1 to prevent tumorigenesis requires further elucidation.
Multiple factors appear to contribute to nuclear localization of BRCA1. BRCA1 binding to BARD1 appears to increase the nuclear accumulation of BRCA1 (7) , presumably by masking the nuclear export sequences of BRCA1 that flank the RING domain (8) . BRCA1-BARD1 binding also appears to stabilize BRCA1 protein expression (9) . Taken together, these two observations suggest that promotion of the nuclear localization of BRCA1 by BARD1 may prevent degradation of BRCA1 by cytosolic 26S proteasomes or other proteases. Finally, nuclear localization of BRCA1 appears to be supported by AKT phosphorylation (10) .
Nuclear localized BRCA1 organizes into discrete foci both during S phase and after DNA damage (11) . Once the DNA damage response is initiated, BRCA1 is recruited to c-H2AX foci in a manner that is dependent on MDC1 (12) , where it participates in the regulation of DNA repair. As the repair process concludes, c-H2AX is removed from the surrounding region (13) .
We were interested in studying whether mutations affecting the RING domain and mutations affecting the BRCT repeat domain have different biochemical consequences for BRCA1 function. We therefore analyzed several characteristics of wild-type, RING mutant (C61G), and BRCT mutant (1853stop) BRCA1 protein expressed in the BRCA1 mutant human breast carcinoma cell line HCC-1937 . This cell line carries the 5382insC mutant BRCA1 allele has lost the wild-type allele, and expresses almost no endogenous BRCA1 (14) . We found that loss of the BRCT repeat domain decreased the halflife of BRCA1 protein and resulted in mostly cytoplasmic localization. In contrast, the RING domain mutant BRCA1 appeared to have similar protein stability and nuclear localization as wild-type BRCA1. However, mutation of either domain appeared to disrupt colocalization of BRCA1 with its protein binding partners BARD1 and BACH1. Furthermore, both types of mutations prevented the recruitment of BRCA1 protein into c-H2AX foci after exposure to ionizing radiation.
MATERIALS AND METHODS

Cell Culture, Chemicals and Recombinant Human Adenovirus
The HCC-1937 cell line is a human breast ductal carcinoma isolated from the primary tumor of a 24-year-old Caucasian female that carries a 5382insC BRCA1 allele. The wild-type BRCA1 allele is deleted. These cells were maintained at 37uC in 95% air/5% CO 2 in RPMI 1640 medium with 1 mM L-glutamine (Gibco, Carlsbad, CA) supplemented with 10% Fetalclone serum (HyClone, Logan, UT) and 1% insulintransferrin-selenium-A (Gibco). Cycloheximide (Calbiochem, San Diego, CA) was dissolved in ethanol and used at a final concentration of 50 mM. Leptomycin B (Calbiochem) was dissolved in methanol and used at a final concentration of 10 nM. Radiation treatments were performed with an RS2000 irradiator (Rad Source Technologies, Inc.).
Recombinant human adenoviruses expressing wild-type BRCA1 (Ad-BRCA1), 1853stop truncated BRCA1 (Ad-1853), or missense C61G BRCA1 (Ad-C61G) were obtained from Drs. Mel Campbell and Roy Jenson (15, 16) . High-titer stocks were generated by infection of HEK-293 packaging cells and CsCl banding (17) followed by dialysis into viral storage buffer (10 mM Tris, pH 7.4, 10 mM histidine, 75 mM NaCl, 1 mM MgCl 2 , 0.1 mM EDTA, 0.5% EtOH v/v, 50% glycerol v/v). Viral concentrations were determined by spectrophotometer and the optical titer of virus particles (VP) was translated to plaque-forming units (PFU) by the calculation of 100 VP 5 1 PFU (18) .
Cells were transduced with adenovirus in suspension. Cells were released from their culture vessels with trypsin, recovered in 37uC culture medium (with serum), and pelleted at 1000 rpm. Cells were resuspended in medium (with serum) at a concentration of 2 3 10 6 cells/ml. Concentrated viral stock was added directly at the multiplicity of infection (MOI) of 100 PFU/cell. Cells were incubated with the virus in suspension at 37uC for 30 min and then plated in the appropriate culture dish and medium.
Immunofluorescence Microscopy
Cells were grown on cell culture grade glass cover slips (Fisher Scientific) for experimental treatments. The cells were fixed with 10% neutral buffered formalin for 10 min and permeabilized for 5 min in 0.2% Triton X-100/PBS. Cover slips were washed three times in PBS and then blocked in 2% BSA/PBS. Dual BRCA1 staining used an Nterminal mouse monoclonal antibody MS13 (1:50; Calbiochem) and an exon 11-directed rabbit polyclonal antibody (1:1250; no. 556443, BD Biosciences/Pharmingen, San Diego, CA) diluted in blocking buffer for 45 min at room temperature. For colocalization studies, BARD1 (rabbit BL-518, Bethyl Laboratories, Montgomery, TX), BACH1 (rabbit no. B 1310, Sigma Aldrich, St. Louis, MO) and c-H2AX (rabbit BL-178, Bethyl Laboratories) were all used at 1:800. For c-H2AX staining, TBS was substituted for PBS in all buffers and washes.
After the primary antibody incubation, cover slips were washed once in PBS/Tween-20 0.05% for 5 min and once in PBS for 5 min, blocked again for 5 min, and then incubated for 30 min with antimouse 594 (1:1000) and anti-rabbit 488 (1:500) (Molecular Probes/ Invitrogen) secondary antibodies in blocking buffer at room temperature. The washes were repeated, nuclei were stained with DAPI, and cover slips were rinsed in water and mounted with antifade fluorescence mounting medium (DAKO). Microscope images were captured at 6003 using a Nikon Eclipse 80i fluorescence microscope and deconvolution was performed with Slidebook software (v4.1, Intelligent Imaging Innovations, Inc., Denver, CO). Quantification was performed manually; at least 200 cells were counted for each experimental group. Cells displaying staining for BRCA1 protein above the background level were considered to be positively stained cells.
Immunoblot Analysis, Immunoprecipitation and Densitometry
Whole cell lysates were prepared in modified RIPA buffer (50 mM Tris base, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.5% Nadeoxycholate, 0.1% SDS, 50 mM NaF, 5 mM Na 3 VO 4 , plus Roche protease inhibitor cocktail tablets). Lysates were incubated for 30 min on ice and clarified by centrifugation at 10,000 rpm at 4uC, and protein concentrations were determined by the Bradford assay (BioRad, Hercules, CA). Then 100 mg of total protein was loaded per lane for Tris-glycine SDS-PAGE on 8% gels. For analysis of proteins smaller than 50 kDa, 12% gels were used. Electrophoresis was performed for approximately 250 V-h at 125 V in running buffer (25 mM Tris base, 192 mM glycine, 0.1% SDS). Samples were transferred to PVDF membranes (Millipore, Billerica, MA) for 200 Vh at 50 V constant at 16uC in 8% transfer buffer (25 mM Tris base, 192 mM glycine, 8% MeOH v/v). Membranes were blocked in 5% nonfat dry milk (Carnation) dissolved in either PBS or TBS (25 mM Tris, pH 8.0, 135 mM NaCl, 2.5 mM KCl) to correspond to the diluent use for the primary antibody. Primary antibody incubations were performed overnight at 4uC. The following primary antibodies were diluted in 0.5% nonfat dry milk/PBS-Tween-20 0.1%: BRCA1 (mouse SD118 and MS110, Calbiochem) at 1:1,000, BARD1 (rabbit BL-518, Bethyl Laboratories) at 1:5,000, BACH1 (rabbit Brip1, Novus Biologicals, Littleton, CO) at 1:5,000, cyclin D1 (rabbit monoclonal SP4, Lab Vision Corp., Fremont, CA) at 1:2,500, tubulin (mouse clone KMX-1, Chemicon) at 1:10,000. c-H2AX (mouse clone JBW301, Upstate Cell Signaling Solutions, Lake Placid, NY) was diluted in 3% BSA (Santa Cruz Biotechnology, Santa Cruz, CA)/ TBS-Tween-20 0.1% at 1:2,500. Anti-mouse and anti-rabbit HRPconjugated secondary antibodies were obtained from Amersham/GE Healthcare (Piscataway, NJ) and diluted 1:10,000 in the same diluent as the primary antibody.
For immunoprecipitation, cells were harvested by a protocol similar to that described above, although cells were lysed in IP lysis buffer (20 mM Tris, pH 8, 120 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% NP-40, 0.25% Na-deoxycholate, 50 mM NaF, 1 mM Na 3 VO 4 , plus Roche protease inhibitor cocktail tablets). One milligram of total protein was diluted in IP buffer (10 mM Tris, pH 7.4, 50 mM NaCl, 5 mM EDTA, 0.5% CHAPS, 50 mM NaF, 1 mM Na 3 VO 4 ), and 1 mg each of MS110 and SD118 BRCA1 antibodies was added with Exacta-Cruz immunoprecipitation matrix (Santa Cruz Biotechnology) according to the manufacturer's protocols. Control immunoprecipitation was performed with 2 mg of antitubulin. SDS-PAGE/Western blotting was performed as described above with the use of Exacta-Cruz secondary antibodies following the manufacturer's protocols.
Densitometry analysis was performed on 600 dpi TIFF scans of films using Quantity One software (Bio-Rad). Global background subtraction was used. Adjusted volume values were normalized using the value for tubulin on that sample as a loading control.
RESULTS
Truncation of the BRCT Domain Decreases BRCA1 Protein Stability and Nuclear Accumulation
To study the biochemical properties of mutant BRCA1 compared to wild-type protein, we used recombinant (Fig. 1a) . Full-length BRCA1 is 1863 amino acids long with a molecular weight of approximately 220 kDa. The RING finger mutation C61G does not alter the protein's size. The 1853stop mutation truncates the protein by 10 amino acids, but the molecular weight difference is insignificant and cannot be clearly resolved on these gels given the large size of the protein. The full-length BRCA1 immunoblot shows several additional bands of lower molecular weight; some of these may represent alternatively spliced isoforms of BRCA1. Analysis of control cells infected with Ad-GFP showed that almost no endogenous BRCA1 protein can be detected in this cell line (similar to control cells transduced with Ad-LacZ or to mock-transduced cells; data not shown). Prior to harvest, quantification of GFP expression in Ad-GFP transduced cell cultures by microscopy indicated that the transduction efficiency is approximately 80% for this cell line under these conditions (data not shown).
We treated similarly transduced cells with the protein synthesis inhibitor cycloheximide (CHX) to determine the protein stability of the mutant BRCA1 proteins compared to wild-type. Protein levels of wild-type and C61G BRCA1 appeared stable over the 12-h time course (Fig. 1b) . Densitometry calculations indicated that the half-life of wild-type BRCA1 is 9.6 h and the half-life of C61G protein is 9.1 h. Conversely, levels of 1853stop BRCA1 were noticeably reduced within 3 h of CHX treatment, with a calculated half-life of 4.7 h. These results were consistent among four independent experiments and indicate that truncation of the C-terminal BRCT repeat domain decreases the stability of the protein significantly.
We also determined the subcellular localization of these forms of BRCA1 by immunofluorescence microscopy. A dual anti-BRCA1 antibody protocol was used to ensure the specificity of the staining protocol (19) . C61G BRCA1 was organized into discrete nuclear foci (Fig. 2a) , similar to the focal nuclear pattern observed with expression of the wild-type protein. However, 1853stop BRCA1 was localized primarily in the cytoplasm (Fig. 2a) . Similar to the immunoblot results (Fig. 1a) , we found that virtually no endogenous BRCA1 could be detected by this staining protocol (Fig. 2a) . Quantification was performed in five independent experiments by scoring the subcellular localization of BRCA1 in positively stained cells as either predominantly nuclear, predominantly cytoplasmic or mixed (Fig. 2b) . Almost 90% of cells expressing wild-type BRCA1 protein exhibited a predominantly nuclear staining pattern compared to only 2% of cells expressing 1853stop protein, which was highly significant. Cells expressing C61G BRCA1 demonstrated a staining pattern similar to that in wild-type cells, although albeit that the proportion of cells with a mixed staining pattern was mildly increased with a concomitant decrease in the percentage of cells with a predominantly nuclear pattern. We attempted to verify these results by subcellular fractionation, but we could not obtain consistent and reliable fractionation with HCC-1937 cells and thus could neither support nor refute our immunofluorescence data with this approach. Overall, these experiments indicate that the BRCT repeat domain is necessary for the efficient nuclear localization of BRCA1 protein, a finding consistent with those of Rodriguez et al. (20) .
Inhibition of Nuclear Export Stabilizes BRCT-Truncated BRCA1 Protein
We hypothesized that the lack of nuclear accumulation of 1853stop BRCA1 may be related to its decreased protein stability compared to wild-type and C61G BRCA1. To test this hypothesis, we treated cells with the nuclear export inhibitor Leptomycin B (LMB). Treatment of cells expressing 1853stop with LMB increased the number of cells exhibiting a predominantly nuclear pattern on immunofluorescence staining (Fig. 3a) . This experiment was performed three times in parallel with staining of untreated cells (representing three of the five experiments represented in Fig. 2 ). Statistical analysis of these matched groups indicated that LMB treatment increased the percentage of cells expressing 1853stop protein in a predominantly nuclear pattern from 2.4% (Fig. 2b) to 28% (Fig. 3b, P ,  0.001) . Correspondingly, the fraction of 1853stop-expressing cells with a predominantly cytoplasmic staining pattern dropped from 61% (Fig. 2b) to 12% (Fig. 3b , P 5 0.02) after LMB treatment. As well, nuclear foci were observed in a proportion of cells expressing 1853stop BRCA1, although these appeared r scored as predominantly nuclear, predominantly cytoplasmic, or mixed. N 5 5 independent experiments; error bars represent SEM. * P , 0.001, {P 5 0.005 by Student's t test.
MUTANT BRCA1 PROTEIN DOES NOT RESPOND TO IONIZING RADIATION to be larger and less defined than wild-type foci (Fig. 3a) , suggesting that the BRCT repeat domain may also be required for the organization of these structures once the protein is localized to the nucleus. Treatment of cells expressing wild-type and C61G BRCA1with LMB (Fig. 3a) did not appear to alter the focal nuclear staining pattern compared to untreated cells (Fig. 2a) and mildly increased the proportion of cells exhibiting a predominantly nuclear staining pattern in both transduction groups. These results suggest that 1853stop BRCA1 can be imported into the nucleus and that an accelerated rate of nuclear export is responsible in part for its cytoplasmic mislocalization in comparison to wild-type and C61G BRCA1.
Therefore, we tested whether the increased nuclear localization of 1853stop BRCA1 in cells treated with LMB affected the apparent stability of the protein. Cells transduced with the BRCA1 expression vectors were pretreated with LMB for 1 h and then subjected to a CHX treatment course, with samples taken at 3, 6, 9 and 12 h. LMB was maintained in the medium during the entire CHX treatment course. Although protein levels of 1853stop did initially decline between 0 and 3 h of CHX treatment, the level of protein remained stable for the rest of the treatment (Fig. 3c) . Densitometry analysis indicated that the half-life of 1853stop protein across the time course was 6.7 h, an increase from 4.7 h in untreated cells (Fig. 1b) . Levels of both wild-type and C61G BRCA1 proteins appeared stable during the course of LMB/CHX treatment ( Fig. 3c ) and had halflives similar to those determined in parallel transduction groups treated with CHX only (Fig. 1b) . In total, these results demonstrate that wild-type BRCA1 is efficiently translocated into the nucleus, where the protein is relatively stable. Mutation of the RING domain (C61G) does not appear to affect the nuclear accumulation of stable BRCA1 protein, but loss of the BRCT domain by truncation severely compromises the nuclear retention of the protein and results in rapid degradation.
BRCT Domain and RING Domain Mutant BRCA1 Fail to Colocalize with BARD1 and BACH1
We next investigated whether either mutant form of BRCA1 demonstrated nuclear colocalization with the BRCA1-interacting protein BARD1 with dual immunofluorescence microscopy. Staining of cells expressing wild-type protein showed clear colocalization of BRCA1 and BARD1 in nuclear foci (Fig. 4a) , a finding that was expected based on previous studies (7, 21) . Staining for 1853stop BRCA1 did not appear to overlap with BARD1 staining even in cells with higher amounts of nuclear localized 1853stop protein. Furthermore, staining for BRCA1 and BARD1 in cells transduced with Ad-C61G demonstrated that these two proteins do not colocalize in vivo despite the fact that C61G BRCA1 was organized into discrete nuclear foci. BARD1 staining in cells expressing either mutant form of BRCA1 was diffusely nuclear compared to the focal staining observed in cells expressing wild-type BRCA1, suggesting that recruitment of BARD1 into these nuclear structures may be dependent on BRCA1.
We also investigated whether the mutant forms of BRCA1 were capable of colocalizing with BACH1. The interaction between BRCA1 and BACH1 is dependent on BACH1 phosphorylation and is mediated by the BRCT repeats of BRCA1 (5) . Therefore, 1853stop BRCA1 should not colocalize with BACH1, an observation that we confirmed in our system (Fig. 4b) . BACH1 and BRCA1 proteins did form distinct colocalized nuclear foci in cells expressing wild-type BRCA1. However, we observed that C61G BRCA1 and BACH1 did not appear to colocalize within the nucleus. Despite the focal nuclear staining of C61G BRCA1, the staining for BACH1 had no clear overlap with the BRCA1 signal. We noted that BACH1 staining was diffusely nuclear in cells expressing either mutant BRCA1 protein, although some faint focal staining was observed, suggesting that organization of BACH1 into distinct nuclear structures may be only partially dependent on BRCA1.
We next sought to determine whether a failure of direct interaction between mutant BRCA1 proteins and either BARD1 or BACH1 might explain the failure to colocalize by immunofluorescence. The 1853stop mutation has been shown to disrupt the direct interaction between BRCA1 and BACH1 (22) . In regard to BARD1-BRCA1 binding, initial work demonstrated that C61G BRCA1 and BARD1 did not interact via coimmunoprecipitation and yeast 2 hybrid approaches (1). However, a subsequent publication showed that the C61G mutation does not disrupt binding to BARD1 using RING domain fragments to study the detailed structure of the interaction (23) . We used our system to determine whether wild-type or mutant BRCA1 proteins expressed in vivo were capable of coimmunoprecipitating both BARD1 and BACH1 from whole cell lysates (Fig. 4c) . Wild-type BRCA1 effectively coimmunoprecipitated both BARD1 and BACH1 proteins. 1853stop BRCA1 was capable of pulling down BARD1, but it failed to interact with BACH1 as expected. C61G BRCA1 coimmunoprecipitated BACH1 protein efficiently, but it was incapable of pulling down BARD1. Therefore, our results clearly demonstrate that the complete 1853stop mutant BRCA1 protein does not interact with BACH1 and that the complete C61G mutant protein does not interact with BARD1 when expressed in vivo. Conversely, interactions are maintained between 1853stop BRCA1 and BARD1 and between C61G BRCA1 and BACH1.
The immunofluorescence studies presented in Figs. 4a and b were performed three times independently. At least 200 cells were analyzed for each condition in each experiment; no instances of multiple, distinct colocalized foci were observed for either mutant form of BRCA1 with either BARD1 or BACH1. Despite this observation, each mutation disrupts only the biochemical interaction of BRCA1 with the protein binding partner of the corresponding domain (RING mutant with BARD1, BRCT mutant with BACH1). Therefore, our results suggest that additional factors are required for the efficient recruitment and maintenance of BRCA1 into nuclear foci with BARD1 and BACH1 beyond direct interaction of these proteins. Mutations affecting either the RING or BRCT domains appear to disrupt BRCA1 colocalization with both of these important protein interaction partners. Furthermore, this failure occurs despite the similarity of nuclear staining patterns observed between C61G mutant and wild-type BRCA1.
BRCT Domain and RING Domain BRCA1 Proteins are not Effectively Recruited to Sites of DNA Damage
Early in the DNA damage response, BRCA1 is recruited to sites of damage that are marked by the phosphorylation of the variant c-H2AX (12). In these damage foci, BRCA1 appears to regulate DNA repair in a manner that is dependent upon the interaction of BRCA1 with BARD1 (24) and BACH1 (5) . Due to the failure of both C61G and 1853stop BRCA1 mutants to colocalize with either BARD1 or BACH1 in the nucleus, we speculated that the recruitment of these mutant BRCA1 proteins to sites of DNA damage might also be impaired. To test this idea, we treated cells expressing either wild-type or mutant BRCA1 with 2 Gy of ionizing radiation, cultured the cells for an additional 2 h, and then immunostained the cells for BRCA1 and c-H2AX. Numerous foci positive for both proteins were observed in cells expressing wild-type BRCA1 (Fig. 5a ). Quantification of three independent experiments demonstrated that 95% of these cells had greater than five nuclear foci positive for both BRCA1 and c-H2AX (Fig. 5b) . On the other hand, less than 10% of cells expressing either 1853stop or C61G BRCA1 protein had more than five nuclear foci staining positively for both the BRCA1 protein and c-H2AX. Furthermore, we continued to observe focal nuclear BRCA1 staining in cells expressing C61G protein after irradiation, but these foci only rarely showed an overlap with c-H2AX staining (Fig. 5a ). These results indicate that both the RING domain and BRCT domain mutant forms of BRCA1 fail to localize at sites of DNA damage.
We also observed that the number of c-H2AX foci per cell 2 h after exposure to 2 Gy was smaller in cells expressing wild-type BRCA1 than in cells expressing either mutant protein or control LacZ. We then analyzed additional times 6 and 10 h after irradiation. Across three independent experiments, the average number of c-H2AX foci was significantly lower at all times examined in cells expressing wild-type BRCA1 compared to cells expressing either mutant form of the protein or control LacZ (Fig. 5c) . Importantly, cells expressing wild-type BRCA1 also demonstrated a significant decrease in the average number of c-H2AX foci per nucleus between 2 h and 10 h, suggesting that resolution of DNA damage foci was occurring. Neither 1853stop-nor C61G BRCA1-expressing cells demonstrated this result.
We further investigated this observation by immunoblot analysis of similarly transduced cells at 2 and 6 h postirradiation compared to cells that had not been irradiated. Untreated cells (represented by time 0) reconstituted with wild-type BRCA1 had less total c-H2AX protein than cells expressing either mutant form of BRCA1 or control GFP (Fig. 6a, lanes 1, 4, 7, 10 ; Fig. 6b ). Two hours after irradiation, all transduction groups demonstrated an increase from baseline in the total level of c-H2AX protein (Fig. 6a, lanes 2, 5, 8, 11 ). Similar to our immunofluorescence data (Fig. 5a, c) , cells expressing wild-type BRCA1 had the lowest level of c-H2AX protein. 1853stop-expressing cells had a modestly higher amount of c-H2AX protein, and both C61G and control GFP groups showed even greater amounts. The data presented in Figs. 5 and 6 are consistent with the DNA repair defect of the HCC-1937 cell line (14) . As these cells traverse S phase of the cell cycle, they accumulate numerous double-strand breaks that are not adequately repaired. This phenotype is rescued by wildtype BRCA1. Therefore, cells reconstituted with wildtype BRCA1 exhibit lower total levels of c-H2AX both before and after irradiation. Total BRCA1 protein levels showed a biphasic response after irradiation, decreasing at 2 h after treatment and then increasing back toward baseline levels or even exceeding these levels by 6 h. BACH1 levels were slightly higher in wild-type and 1853stop-expressing groups, but this was not a consistent finding over three independent experiments. On the other hand, BARD1 protein levels were consistently increased by expression of either wild-type or 1853stop BRCA1, and BARD1 levels varied similarly after irradiation in parallel with BRCA1. The protein-protein interaction between either wild-type or 1853stop Cells expressing the indicated forms of BRCA1 protein were exposed to 2 Gy and cultured prior to fixation. Cells were stained with a monoclonal antibody against BRCA1 (red) and a polyclonal antibody against c-H2AX (green). Wild-type BRCA1 is recruited to c-H2AX foci, but both mutant forms of BRCA1 fail. The experiment was performed three times. Panel B: Quantification of colocalized BRCA1 and c-H2AX foci 2 h after irradiation. Two hundred cells stained positively for BRCA1 were scored for the number of nuclear foci demonstrating colocalization of BRCA1 and BARD1 (Fig. 4c ) may explain this observation, because previous work has shown that the BRCA1-BARD1 interaction stabilizes expression of both proteins (9) .
DISCUSSION
The ability of BRCA1 to regulate DNA repair is likely a critical aspect of its tumor suppressor function. Mutations within both structural domains of BRCA1 predispose individuals to hereditary cancer syndromes (6) , which indicates that the function of both domains is important for the suppression of tumorigenesis. In this work, we show that mutations that affect either the RING domain or the BRCT repeats both disrupt a critical step in the response to DNA damage: recruitment of BRCA1 to c-H2AX-positive foci at sites of damage. We also demonstrate that mutation in either the RING domain or the BRCT repeats decreases the colocalization of BRCA1 with two important proteinbinding partners, BARD1 and BACH1.
The phenotype of RING mutant (C61G) BRCA1 protein is similar to that of the wild-type protein in regard to nuclear localization and protein stability despite the lack of clear colocalization between BRCA1 and BARD1. This observation appears to conflict with a previous report that suggests BARD1 is responsible for the nuclear retention and stabilization of BRCA1 (7). In our model, C61G mutant BRCA1 cannot interact directly with BARD1, nor does it demonstrate nuclear colocalization with BARD1 on immunofluorescence staining. Nevertheless, the C61G protein itself does translocate to the nucleus and aggregate into nuclear foci, and it appears to have a half-life similar to that of the wild-type protein. Therefore, our results suggest that the interaction of BRCA1 with BARD1 is not absolutely necessary for nuclear retention or regulation of protein stability. However, the failure of C61G BRCA1 to interact with BARD1 may underlie the lack of C61G recruitment to sites of DNA damage after irradiation and the higher levels of c-H2AX observed in this transduction group.
The failure of C61G BRCA1 to colocalize with BACH1 also has interesting implications for the in vivo regulation of BRCA1 subnuclear targeting. The phospho-protein binding pocket created by the C-terminal BRCT repeats of BRCA1 mediates the direct proteinprotein contacts with BACH1, and the RING mutation does not disrupt the direct interaction (Fig. 4c) . The fact that neither mutant BRCA1 protein localizes with either BACH1 or BARD1 suggests that additional regulatory mechanisms, which require both BRCA1 structural domains, likely target BRCA1 into nuclear structures with its functional binding partners BARD1 and BACH1.
Finally, our results indicate that both the RING domain and the BRCT repeats are required for the targeting of BRCA1 to DNA damage sites after irradiation. This finding reinforces the concept of additional regulatory mechanisms of BRCA1 subnuclear localization, consistent with a previous report (25) . The total levels of c-H2AX protein are increased in the HCC-1937 cell line secondary to the BRCA1-null DNA repair deficiency (14) . Wild-type BRCA1 expression decreases total c-H2AX levels at baseline to a much greater degree than either mutant protein compared to controls. c-H2AX levels are also lower in wild-type expressing cells at both times after irradiation compared to either mutant group or control, suggesting that DNA repair efficiency is improved in the wild-type group.
Our observation of a focal pattern of BRCA1 staining in the absence of ionizing radiation is consistent with the results shown by Au (25) but expands on this study by showing differences between the effects of BRCA1 mutants and wild-type BRCA1 on c-H2AX. The results of study differ from those of Rodriguez (20) by showing that both the RING domain and the BRCT domain appear to be required for the targeting of BRCA1 to nuclear damage sites and by indicating that neither mutant protein localizes with BARD1 or BACH1, suggesting that additional regulatory mechanisms are responsible for proper BRCA1 function.
This work demonstrates that, despite significant differences in the biological characteristics of 1853stop BRCA1 compared to C61G BRCA1, both mutant forms are not recruited to sites of DNA damage and both fail to colocalize with important functional binding partners. Further work addressing the mechanisms of how mutations in either the RING or the BRCT domain severely disrupt the nuclear trafficking of BRCA1 will increase our understanding of tumorigenesis associated with BRCA1 mutation. r BRCA1 and c-H2AX proteins. N 5 3; error bars represent SEM. *P , 0.001 for both wild-type compared to 1853stop and wild-type compared to C61G, Student's t test. Panel C: Quantification of c-H2AX foci per nucleus. The number of foci per nuclei was counted in 10 representative high-power fields for each group within each experiment (approximately 50 nuclei per group). N 5 3; error bars represent SEM. BRCA1 groups compared to 1853stop, C61G and LacZ at 2 (*), 6 (+) and 10 h ({) (P # 0.02 for all comparisons, Student's t test). The decreased number of foci/ nucleus in BRCA1 groups between 2 and 10 h (**) was also significant (P 5 0.001, Student's t test). 
